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ABSTRACT 
INTRODUCTION:  Worldwide, there is a paradigm shift in the screening for 
cervical cancer with the use of high-risk human papillomavirus (hrHPV) 
molecular testing. Before South Africa (SA) adopts this technology in the 
public sector, health funders will need data on the performance of the current 
cytology and colposcopy-based programmes. This study was done to establish 
baseline data on the performance of the cytology and colposcopy based cervical 
cancer screening programme at the Groote Schuur Hospital (GSH) colposcopy 
clinic. 
METHODS: This was a retrospective cohort study of all the women with high-
grade squamous intraepithelial lesion (HSIL) Pap smears seen at GSH 
colposcopy clinic between 01 January 2010 and 31 December 2015. The 
outcome measures were; diagnostic concordance between cytology, 
colposcopy and histology, large loop excision of the transformation zone 
(LLETZ) and cone biopsy complication rates, cure rate, treatment failure and 
invasive cervical cancer rates, median time from treatment to recurrence, 
follow-up default rates. Data were managed and analysed using IBM SPSS 
Statistics Version 25 and Microsoft Structured Query Language (SQL) version 
2014. Regression methods were used to assess the independent effect of 
baseline sociodemographic characteristics and clinical covariates on treatment 
failure and clearance of disease in those who had persistent disease after 
treatment. Kaplan-Meier curves were used to represent the time from 
treatment to recurrence and from persistence to cure. Time-to-event methods 
were applied to determine factors associated with treatment to recurrence and 
persistence to cure.   
 
RESULTS: A total of 7601 women were referred to the GSH colposcopy clinic 
during the study period. HSIL or worse lesions (≥HSIL) were confirmed 
histologically in 74.1% (2282/3081) women.  At the four-month follow-up 
visit, 61.2% (742/1213) of the women were considered cured, and 17.0% 
(206/1213) had persistent/residual disease. In women considered cured at 
11 
four months, recurrence was very low, and it peaked at ten months at 1.5% 
(11/740).  By 24 months the cumulative recurrence rate was 4.6% (34/742).  In 
women with persistent disease at the four-month follow-up visit, only 0.5% 
(1/202) developed invasive cervical cancer. The default rate for follow-up was 
very high, at 81% at 24 months. LLETZ and cone biopsy complication rate was 
7.2% (117/1628). Log-rank analysis showed that parity ≥ four was significantly 
associated with a higher risk of disease recurrence (p=0.0004). In a Cox-
regression model, taking HAART was the only factor associated with a reduced 
risk of disease recurrence (p=0.0261).  
CONCLUSION: LLETZ and cone biopsy are safe procedures. After cure, 
recurrence rates are low. In women who are treated for HSIL, cervical cancer 
is very rare. Taking HAART was associated with a reduced risk of disease 
recurrence. There is a need to mitigate on higher default rates to follow up. 
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CHAPTER 1: INTRODUCTION AND LITERATURE 
REVIEW 
1.1. Background (Epidemiology, aetiology, secondary prevention, 
colposcopy, treatment, follow-up and Groote Schuur hospital practice) 
1.1.1. Epidemiology 
According to the International Agency for Research on Cancer (IARC GLOBOCAN 
2012 database), cervical cancer is the fourth most common cancer in women worldwide 
and the commonest in women aged between 15- 44 years (1).  In 2012, 528 000 women 
were diagnosed with cervical cancer, and 266 000 of them died from the disease. 
Unfortunately, 85% of these deaths occurred in under-resourced countries where there 
are no effective cervical cancer screening programmes and the burden of human 
immunodeficiency virus (HIV) infection is high (1). Prevalence of cervical cancer and 
deaths are higher in countries with low human development index (HDI), with five-
year survival rates being less than 20% in these countries compared to over 65% in 
countries with very high HDI (2). In countries that have introduced organised cervical 
cancer screening, mortality has fallen significantly. In countries with opportunistic 
screening or without screening programmes, mortality has remained high (3, 4). 
Currently, cytology through a call and recall system is the most effective screening 
method available (every 3 – 5 years women are reminded to go for a repeat Pap smear). 
Cytology-based screening requires a relatively sophisticated laboratory set-up with 
appropriate equipment and technical support, built-in quality control, trained staff and 
a health system underpinned by good referral pathways. This system has been shown 
to reduce significantly cervical cancer incidence, morbidity and mortality especially 
when linked to accessible colposcopy and treatment services. Before 2012, the cost of 
the cervical cancer screening programme in the United States of America (USA) 
reached 6 billion dollars (5). Most low-resourced countries have not been able to set 
up effective cytology-based screening programmes due to these astronomical costs, 
and screening remains opportunistic if available at all.  
South Africa (SA) is an upper-middle- income country with huge disparities in cervical 
cancer screening practices in the public and private sectors. In a study done in three 
districts of SA, only 50% of women with high-grade squamous intraepithelial lesions 
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(HSIL) Pap smears had colposcopy and biopsy within six months (6).  In the Free State 
Province of SA, only 4.1% of women aged between 15 to 65 years were screened in 2002, 
a decrease of 42% compared to 1985. Only 2.6% were black women utilising mostly the 
public sector compared to 18.8% white women who had their screening in the private 
sector (7). Although infection with the human immunodeficiency virus (HIV) is a 
known risk factor for HSIL and cervical cancer, only 13.1% of newly diagnosed HIV- 
positive women had at least one Pap smear in primary HIV clinics in Cape Town 
between 2006- 2008 (8). In 2001, the South African Department of Health introduced 
a cervical cancer screening programme. The programme offered all asymptomatic 
women three free Pap smears in their lifetime at the ages of 30, 40 and 50 years but 
women with gynaecological problems were offered a Pap smear regardless of their 
screening history or age (9). Incidence and mortality of cervical cancer remain high in 
South Africa.  In 1998-1999, there were 6061 and 5203 new cases of cervical cancer 
respectively giving an age-standardised incidence rate (ASIR) of 42-35/100 000 
respectively. Mortality in the two year period was nearly 60% (10). In this study, we 
describe the long-term outcomes of women treated for HSIL in the GSH colposcopy 
clinic. 
  
1.1.2. Aetiologic factors 
1.1.2.1. HPV infection 
The human papillomaviruses (HPV) are small double-stranded deoxyribonucleic acid 
(DNA) viruses enclosed in a 72- sided icosahedral protein capsid. They have around 
8000 nucleotide base pairs, and they are known to infect the human epithelia. The 
HPV genetic material is divided into E (early) or L (late) genes. During epithelial 
differentiation, the E and L genes are expressed early and late respectively (11). More 
than 100 HPV subtypes have been fully sequenced, and after sequencing, they are 
divided into phylogenetic trees which make it easier to understand their classification 
and behaviour (12). Human papillomaviruses are also divided into different groups 
depending on the pathology they cause; these groups are known as clades. Clades 
alpha-7 and nine are strongly associated with anogenital cancers. HPV 16,  a clade 
alpha- 9 virus, is one of the most powerful human carcinogens known to date, is 
responsible for about 50% of cervical carcinoma cases (12). In total, 15 anogenital types 
are associated with an increased risk of developing cancer, and these are called 
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oncogenic or high-risk human papillomavirus (hrHPV) types. These oncogenic HPV 
subtypes include; 16, 18, 31, 33, 35, 45, 52, and 58 (13). The contribution of the other 
hrHPV types; 39, 51, 56, 59, 66, 68 and 73 is less certain (14). HPV 6 and 11 are clade 
alpha-10 viruses, they are called low-risk HPV (lrHPV) types. They mostly cause genital 
warts and low-grade squamous intraepithelial lesions (LSIL).  
The HPV normally survives in the host nucleus separate from the host genome as a 
stable viral episome.  However, to develop HSIL and invasive cancer, the HPV genome 
needs to be integrated into the host genome (15). This process of integration is 
controlled by the E1 and E2 genes (16). The L1 and L2 genes are responsible for 
encoding the common viral capsid proteins. The E6 and E7 genes of the hrHPV types 
encode for oncoproteins which disrupt the control of the cell cycle resulting in 
immortalisation of keratinocytes. The E6 oncoproteins of the hr-HPV types induce 
degradation of the tumour suppressor p53 protein which is encoded by the tumour 
suppressor gene p53, resulting in loss of p53 control of the cell cycle (17). The E7 
oncoproteins interact and deactivate the product of the retinoblastoma gene (pRB). 
The RB gene is a tumour suppressor which inhibits the cell cycle (18). Therefore, the 
combined action of the E6 and E7 oncoproteins is a necessary step in the 
transformation of cells and the development of cervical cancer.    
However, due to humoral and cellular-mediated immunity, the majority of women 
exposed to HPV infection can clear the infection within 24 months (19, 20). Persistence 
of the oncogenic HPV infection is the biggest risk factor for developing HSIL (20). This 
risk is not dose-dependent, and therefore, it is not modified by measuring the HPV 
viral load in the genital tract (11). Compared to lrHPV types, persistent infections are 
more likely with the hrHPV groups (21). In a United States of America cohort, hrHPV 
16 infection at baseline was associated with a 14.6% and 8.5% risk of developing ≥ HSIL 
in women less and greater than 30 years respectively. In the same cohort, in hrHPV 16 
naïve women, the risk of developing ≥ HSIL was less than 2% in both groups of women 
(22). In one of the world’s most notorious unethical studies, Professor Herbert Green 
working at New Women’s Hospital in Auckland, New- Zealand withheld curative 
treatment from women with CIN 3 from 1965 to 1974. Analysis of this data showed that 
thirty per cent of women with HSIL would progress to cervical cancer in about 30 years 
if left untreated (23). This long latent period allows for the Pap smear to be frequently 
repeated and is responsible for the relatively high longitudinal sensitivity of cytology. 
15 
1.1.2.2. Associated co-factors 
1.1.2.2.1. Tobacco 
Both active and passive smoking have been shown to increase the risk of developing 
HSIL (24). The risk is dose-dependent, and it also depends on the age of initiating 
smoking (25). The mechanism of action could be due to direct effect from the 
breakdown products of tobacco which have been isolated in cervical secretions or the 
depletion of the epithelial antigen-presenting Langerhans cells which leads to failure 
in clearing the HPV infection resulting in viral persistence and ultimately HSIL (26). 
Smoking is not associated with an increased risk of developing cervical 
adenocarcinomas (25). 
1.1.2.2.2 Hormonal factors 
Higher rates of genital HPV infection especially type 16 have been found in pregnancy, 
which supports the theory that the hormonal milieu of pregnancy supports viral 
replication (27). The prevalence of HPV infection increases dramatically from the first 
to the third trimester followed by a sharp decline post-delivery (28). Pregnancy before 
the age of 17 years and multiparity have been associated with a higher risk of 
developing cervical cancer (29). Prolonged exposure to contraceptives is also a known 
risk factor for cervical cancer (30). 
1.1.2.2.3. Immunosuppression  
HIV infection increases the risk of developing HSIL which is related to the degree of 
immunosuppression (31).  However, a recent study has questioned the association 
between the level of immunosuppression and prevalence of abnormal Pap smears (32). 
The risk of harbouring multiple HPV infections is also higher in HIV- infected women 
(33).  Co-infection with both HIV and hr-HPV increases the risk of developing cervical 
squamous intraepithelial lesions (SIL) 40- fold (34). Due to the lifelong use of 
immunosuppressive therapy, renal transplant patients have a 16-fold higher risk of 
developing cervical SIL compared to the general population (35). However, a recent 
study has also questioned this association (36). 
1.1.3. Secondary prevention 
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Secondary prevention or cervical cancer screening has been historically done by 
examination of fixed exfoliated cervical cells under a microscope (Pap smear). It needs 
to start at an appropriate age to maximise benefit and minimise harm due to the 
treatment of transient cervical changes due to HPV infections. In a population-based 
case-control study, screening for cervical cancer below the age of 25 years was not 
shown to reduce the incidence of cervical cancer at the ages of 25- 29 years (37).  The 
International Agency for Research on Cancer (IARC) in 2006 recommended 3- 5 yearly 
screening intervals between the ages of 25 to 65 years (3). Shorter screening intervals 
have not been shown to be more effective (4). This recommendation is followed by the 
United Kingdom National Health Service Cervical Screening Programme (NHSCSP), 
one of the most successful cervical cancer screening programmes in the world (38). 
However, the American society for colposcopy and cervical pathology (ASCCP) still 
recommend screening from the age of 21 years (39).  
 
1.1.3.1. Cytology 
Due to the lack of a more sensitive alternative, the Pap smear has been the screening 
method of choice in most established cervical cancer screening programmes. Reviews 
have shown the sensitivity of cytology to be between 50-60% (40, 41). Regular 
screening increases the longitudinal sensitivity of cytology, but this makes screening 
more expensive. Liquid-based cytology (LBC) which uses a brush to collect cervical 
cells and transport them in a buffered alcohol media was introduced as a way to try and 
improve the sensitivity of conventional cytology. However, its performance is similar 
to conventional cytology (42, 43). LBC reduces the number of inadequate smears which 
makes its use cost-effective (44, 45). SA migrated to LBC screening in 2017. HPV 
testing or co-testing can be done with LBC, so the introduction of LBC paves the way 
for HPV testing as a primary screening method. 
 
1.1.3.2. HPV DNA 
Understanding the role of hrHPV in the development of cervical cancer has accelerated 
research in cervical cancer screening. Currently, hrHPV molecular testing is used as a 
test of cure, in triaging women with atypical squamous cells of undetermined 
significance (ASC-US) cytology results, co-testing with cytology and in primary 
screening.  
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A meta-analysis showed that hrHPV molecular test of cure was more sensitive than 
conventional cytology by 21-25% (46). Molecular testing of hrHPV also results in 
earlier detection of residual or recurrent disease (47). Test of cure using hrHPV 
molecular testing was introduced in the NHSCSP in the UK after successful pilot 
studies showed that this approach was safe and 82% of women could safely be referred 
back to routine screening (48). Modelling studies also confirmed the clinical and cost-
effectiveness of this approach compared to follow-up with annual cytology (49). 
However, the use of a hrHPV molecular test of cure has not been internationally 
accepted. Some studies have shown this approach to be less cost-effective (50) and less 
reassuring than co-testing with cytology (51). 
Another role of hrHPV molecular testing is in triaging women with ASC-US Pap 
smears. The ASC-US/LSIL triage study (ALTS) showed that hrHPV molecular testing 
in women with ASCU-US Pap smears was as sensitive as immediate colposcopy in 
detecting ≥HSIL with half as many women referred for colposcopy (52). Use of this 
strategy in women with LSIL Pap smears has a much lower specificity compared to 
cytology (46).  
Molecular testing of hrHPV is more sensitive and reproducible compared to cytology 
and screening intervals can be safely increased to at least five years (53). As a primary 
screening tool, hrHPV molecular testing detects more ≥ HSIL in the initial round of 
screening with less disease being picked up in subsequent screening rounds (54). HPV 
based primary screening is more effective than cytology in reducing invasive cervical 
cancer (55, 56). New techniques which can partially genotype HPV types 16 and 18 
which are responsible for 70% of cervical cancer cases are now available and have 
found use in stratifying care of some women (57). However, worldwide, the use of HPV 
testing faces resistance in some societies due to associated stigma and shame of a 
positive result (58). 
The Netherlands was the first country to implement hrHPV molecular testing as a 
primary screening modality for cervical cancer. 
1.1.3.3. Other screening techniques 
Visual inspection of the cervix with acetic acid (VIA) utilises 3-5% acetic acid to 
visualise aceto-white lesions close to the transformation zone with a bright light using 
naked eyes alone or with the help of low-level magnification (VIAM). VIA is cheap and 
easy to perform and its sensitivity and specificity range from 49-96 per cent and 49- 
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98 per cent respectively (59). In one Indian study, after four rounds of cancer education 
and VIA screening at 24-month intervals, cervical cancer mortality was reduced by 31% 
after 12 years of follow-up (60). Using a conditional probability model, VIA combined 
with digital cervicography was shown to prevent one cervical cancer death for every 
forty-six HIV-infected women screened in Zambia (61). In Africa, the efficacy of VIA is 
comparable to cytology (62), but its major weakness is a low positive predictive (PPV) 
value of only 10% (63). VIA results in overtreatment of a large number of women 
without HSIL. VIA is also less effective in older women. The combination of VIA and 
visual inspection with Lugol's iodine (VILI) has been shown to be a cost-effective tool 
requiring minimal medical resources in remote areas (64). 
 
1.1.4. Colposcopy 
HSIL Pap smears and positive hrHPV molecular tests are the commonest indications 
for colposcopy referral. Symptomatic women with abnormal looking cervices or 
unexplained intermenstrual bleeding (IMB), post-coital bleeding (PCB) or persistent 
vaginal discharge should also be referred for colposcopy. Women with ASC-US/LSIL 
Pap smears can also be immediately referred for colposcopy, triaged with hrHPV 
molecular testing or followed up by cytology. In the Western Cape Province, women 
are referred for colposcopy if they have two consecutive Pap smears showing ASC-US 
or LSIL since hrHPV molecular testing is not available in the public sector. Colposcopy 
can be normal, show minor or major changes or lesions suspicious of microinvasive 
disease. There is an overall agreement of 92% between colposcopic assessment and 
histological diagnosis of ≥ HSIL and adenocarcinoma in-situ (AIS) (65).  There is need 
to continuously audit colposcopy practice in cervical cancer screening programmes to 
minimise under or overdiagnosis of HSIL resulting in missed disease or unnecessary 
treatment by excisional methods which can lead to adverse obstetric consequences 
(66). Some units have adopted various scoring systems to improve accuracy in 
colposcopic assessment.  
 
1.1.5. Treatment 
Historically, hysterectomy was the standard of care for treatment of women with 
carcinoma in-situ. Cone biopsy was adopted after studies showed similar efficacy to 
hysterectomy in the prevention of invasive cervical cancer (67). Colposcopically 
19 
directed biopsies were later shown to be as effective as cone biopsies in the diagnosis 
of HSIL (68). The acceptance of colposcopically directed biopsies as an effective 
diagnostic tool led to the introduction of ablative treatment modalities so that women 
could retain their reproductive potential. Cryotherapy was shown to have lower cure 
rates in women with endocervical involvement (69). Electrocoagulation diathermy 
have HSIL cure rates >95% (70). Laser treatment is also used to treat HSIL effectively. 
The majority of cases of women who develop invasive cervical cancer after ablative 
treatment are due to pre-treatment misdiagnosis of micro-invasive disease (71). 
Availability of histopathological specimens to exclude micro-invasive disease led to 
large loop excision of the transformation zone (LLETZ) gaining widespread popularity. 
Colposcopy can be combined with immediate treatment using LLETZ or ablative 
techniques. Treating women at the same sitting with colposcopy is commonly referred 
to as ‘see and treat’. ‘See and treat’ is an effective and safe technique that can be used 
in low- resource countries where follow-up default rates are high (72). 
1.1.6. Follow-up 
For women with HSIL, AIS or micro-invasive (MI) disease, their risk of HSIL remains 
high for many years even after an initial negative post-treatment cytology result (73).  
The National Health Service Cervical Screening Programme (NHSCSP) in the UK 
allows women with negative, ASC-US or LSIL Pap smears to be returned to routine 
screening if the hrHPV molecular test of cure is negative at six months post-treatment 
(38). The ASCCP guidelines recommend co-testing at 12 and 24 months and referral to 
colposcopy if any one of the test results is abnormal (39). 
1.1.7. GSH colposcopy clinic practice 
SA has not yet introduced hrHPV molecular testing into its public cervical cancer 
screening programme. At Groote Schuur Hospital, women are mostly referred to the 
colposcopy clinic for HSIL, two consecutive ASC-US, and LSIL Pap smears. Women 
are also referred for any glandular abnormality on Pap smear or clinically suspicious 
cervices regardless of the cytology results. Women with adequate colposcopy 
confirming major changes after presenting with HSIL Pap smears are treated with an 
LLETZ procedure. Concordance between cytology and colposcopy is around 80% (74), 
so many women at GSH colposcopy clinic are treated at the same visit (‘see and treat’) 
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to minimise the impact of loss to follow-up. Women with HSIL Pap smears and 
inadequate colposcopic findings or have a discrepancy between cytology and 
colposcopy have a diagnostic cone biopsy done instead. Some colposcopists prefer 
doing a diagnostic punch biopsy before definitive treatment.  
All the women above the age of 45 years with abnormal glandular cells on Pap smear 
also have their endometrium sampled to exclude uterine pathology. Women with 
colposcopic and histologically-confirmed LSIL are not treated because regression rates 
are high, especially in young women and progression to ≥HSIL is uncommon (75) 
Every woman is brought back to the clinic after 4-6 months post-treatment, and if 
repeat cytology and colposcopy exclude HSIL, they are recalled every 6-12 months for 
repeat colposcopy and cytology for ten years before they go back to routine screening. 
If colposcopy shows major changes and or cytology shows HSIL, patients are treated 
again with an excisional procedure after diagnosis has been confirmed histologically 
via a punch biopsy specimen.  
 
1.2. The justification for the study 
At the moment, there is a paradigm shift in the world in how cervical cancer screening 
is performed. High-risk HPV molecular testing is being utilised as a primary screening 
tool, co-testing with cytology, triaging of ASC-US/LSIL Pap smears and as a test of cure 
in many high-income countries. The use of hrHPV molecular testing in cervical cancer 
screening programmes in low-income countries is feasible (76). In the private sector in 
South Africa, hrHPV molecular testing is already being widely used in cervical cancer 
screening. However, before this is adopted in the public sector, health funders will need 
robust data on both how the current cytology-based programme is performing, and the 
feasibility of using hrHPV testing in an SA population with high rates of co-infection 
with HIV and HPV. This study, although from a single institution, is essential as it will 
provide some baseline data on the performance of the current cytology-based cervical 
cancer screening programme in the local population. After the inevitable introduction 
of hrHPV molecular testing, its impact will need to be audited, and the baseline data of 
the current programme will be needed for comparison. 
 
1.2.1 Research Question: 
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What are the oncological and operative outcomes of women with HSIL treated with an 
excisional procedure (LLETZ/cone biopsy) at GSH colposcopy unit? 
 
 
 
2. STUDY OBJECTIVES 
 
2.1 Main Objective 
To evaluate the oncological and operative outcomes of women with HSIL treated with 
an excisional procedure (LLETZ/cone biopsy) at GSH colposcopy unit. 
2.2 Secondary objectives of the study 
 To document the number of women referred for HSIL Pap smears as a proportion 
of the total number of women referred to the GSH colposcopy clinic during the 
study period. 
 To describe the baseline sociodemographic and clinical parameters of women 
referred for HSIL Pap smears to GSH colposcopy clinic during the study period. 
 To document the proportion of women who had colposcopy followed by either 
immediate treatment with LLETZ (see and treat) or immediate diagnostic cone 
biopsy or a diagnostic punch biopsy before definitive treatment. 
 To determine the diagnostic concordance between cytology, colposcopy and 
histology. 
 To document the proportion of women who reported complications after LLETZ 
or cone biopsy. 
 To document the proportion of women with treatment failure after excisional 
treatment which was defined as either residual/persistent or recurrent disease. 
 To calculate the median time from treatment to recurrence. 
 To document the proportion of women who developed invasive cervical cancer 
after excisional treatment of HSIL. 
 To calculate the follow-up default rate. 
 To define the baseline sociodemographic and clinical parameters associated with 
failure of HSIL treatment by an excisional procedure (residual/persistent or 
recurrent disease).  
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CHAPTER 2: MATERIALS AND METHODS 
 
This was a retrospective descriptive study. The protocol was approved by the Human 
Research Ethics Committee of the University of Cape Town on 28 June 2017 (HREC 
Ref: 445/2017) (see appendix 1). Approval was also granted by GSH to retrieve old 
colposcopy folders and clinical notes as and when required to update missing data (see 
appendix 2). 
2.1. Study outcomes measures 
 Diagnostic concordance between cytology, colposcopy and histology 
 Excisional procedure (LLETZ and cone biopsy) complication rate 
 Post- HSIL treatment cure rate 
 Median time from treatment to recurrence 
 Post- HSIL treatment persistent or recurrence rates 
 Post-HSIL treatment invasive cervical cancer rate 
 Follow-up default rate 
 
2.2. Data collection 
Since 2007 all the women who were referred to the GSH colposcopy clinic have been 
entered into a computerised database which has the Human Research Ethics 
Committee (HREC) approval. After HREC approval for the study was granted, the 
database was screened to exclude women who did not meet the inclusion criteria. All 
those who met the inclusion criteria had their data extracted and analysed. We 
retrieved 900 colposcopy folders and clinical notes to update essential data which was 
missing from the database.  
From the database, we extracted the following sociodemographic and clinical 
parameters; age, parity, menopausal status, contraception use, smoking status, HIV 
status, antiretroviral drug use, most recent CD4+ count, and medical comorbidities 
like previous or current infection with tuberculosis or diabetes mellitus. We also 
extracted the women’s colposcopy, cytology and histology results for all their 
subsequent visits for the whole duration of the study.  
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Excisional procedures were either a LLETZ 0r a diagnostic cone biopsy and they were 
defined as follows; LLETZ (type 1 or 2 excision) is a therapeutic procedure done after 
colposcopic identification of a precancerous lesion and the following criteria has to be 
met before it is done; concordance between cytology and colposcopy results, the whole 
lesion has to be visualised, no suspicion of microinvasive disease and no glandular 
abnormality on cytology. When these criteria are not met, a diagnostic cone biopsy 
(type 3 excision) is done. A diagnostic cone biopsy can be therapeutic if the whole lesion 
is excised. 
We also extracted the reported complications from the database. All this data were 
entered on IBM SPSS Statistics Version 25 for analysis.  
2.3. Participants entry into the study 
2.3.1 Pre-recruitment evaluations  
The database was screened to exclude women who did not meet the inclusion criteria 
from the analysis. 
2.3.2. Inclusion criteria 
 Confirmed HSIL Pap smear at referral 
2.3.3. Exclusion criteria     
 No confirmed HSIL Pap smear at referral 
 Women with no results recorded in the database 
     2.4. Statistics and data analysis 
2.4.1. Sample size 
We included all the women who were referred to GSH between 01 January 2010 and 
31 December 2015 who had HSIL Pap smears and follow-up results captured in the 
database.   
2.4.2. Data analysis 
Data were managed and analysed in IBM SPSS Statistics Version 25 and Microsoft 
Structured Query Language (SQL) version 2014. Demographic characteristics and 
clinical factors were summarised using median and range, and percentages for 
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continuous and categorical variables respectively. We documented the management of 
the women on their first visit and calculated the proportion of those who had 
colposcopy followed by immediate treatment with LLETZ (see and treat) or a 
diagnostic cone biopsy and those who had a diagnostic punch biopsy before definitive 
treatment. We also documented the women’s colposcopic findings and the final 
histology results for their initial referral visit.  The final histology results were either 
from LLETZ, cone biopsy or diagnostic punch biopsy specimens. Diagnostic 
concordance between cytology and histology as the gold standard in detecting ≥HSIL 
was documented. Using the histological diagnosis as the gold standard, we also 
calculated the sensitivity, specificity, positive and negative predictive values and 
diagnostic accuracy of colposcopy in detecting ≥HSIL. We then calculated the 
diagnostic concordance between cytology and histology in detecting ≥HSIL in women 
who had colposcopic assessment followed by immediate LLETZ (see and treat) or 
diagnostic cone biopsy. We also calculated the concordance between colposcopy and 
histology in detecting ≥HSIL in women who had immediate treatment with LLETZ 
only. We then calculated the concordance between colposcopy and histology in 
detecting ≥HSIL in women who had a diagnostic cone biopsy. We also described the 
complications reported by the women on their four-month post-treatment follow-up 
visit. We used the women’s four-month post-treatment cytology and or colposcopy 
results to put them into two categories; either persistent/residual disease or cured.  We 
defined persistent or residual disease as any woman who had excisional treatment of 
HSIL and on the four-month follow-up visit had either major colposcopic findings and 
or ≥ ASC-H Pap smear. We defined a cure as any woman who had excisional treatment 
of HSIL, and on the four-month follow-up visit, had normal colposcopy findings and 
Pap smear results. Women who had minor colposcopic findings and or ASC-US or LSIL 
Pap smears were excluded since there was no hrHPV molecular testing to triage them 
into the persistent/residual disease or cured category. The colposcopy and or cytology 
and or histology results of all the subsequent visits of women in these two groups were 
extracted and analysed. We did not expect any woman to be discharged from follow-
up during the study period because at GSH colposcopy clinic all women treated for 
HSIL are followed up closely for at least ten years. Women were defined to have 
recurred if they had any one of the following; major changes at colposcopy and or 
≥ASC-H Pap smear and or HSIL histology after prior documented normal colposcopy 
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and histology results. Women who developed cancer and those who defaulted follow-
up were also documented. Histology results in the database were searched for any 
hysterectomy histopathology results. Univariate association between treatment failure 
and sociodemographic and clinical parameters was evaluated using the chi-squared 
test, t-and non-parametric tests. Regression methods were used to assess the 
independent effect of baseline sociodemographic characteristics and clinical covariates 
on study outcome (failure of HSIL treatment by LLETZ or cone biopsy). The time from 
treatment to recurrence was determined and presented on a Kaplan-Meier curve. In 
women who had persistent/residual disease, the time to clearance of disease after 
retreatment was also presented on a Kaplan-Meier curve. Time-to-event methods were 
applied to determine factors associated with recurrence after cure and clearance of 
disease after retreatment in those who had persistent/residual disease.  
2.5. Regulatory issues 
2.5.1. Confidentiality  
We complied with data protection legislation to preserve the confidentiality of women 
involved in the study. The colposcopy clinic database and all the computers used to 
store and analyse data were password protected. 
2.5.2. Sponsor 
The University of Cape Town and the South African Medical Research 
Council/Gynaecology Cancer Research Centre (SAMRC/GCRC) were the main 
sponsors for this study.   
2.6. Publication policy 
Authorship will be based on substantial contribution to conception, design, analysis, 
interpretation of data, drafting and approval of the version to be published. 
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CHAPTER 3: RESULTS 
 
Summary of table 1 
The women’s ages ranged from 18 to 83 with a median of 37, and their parity ranged from 
0 to 10 with a median of 2. The group was predominantly premenopausal 84.3% 
(3384/4012). More than a third of the women were not using any contraception 42.1% 
(1435/3408) and 40.1% (1367/3408) were using injectable progestogen contraception 
(IPC). Less than a tenth 8.8% (300/3408) of the women had undergone tubal ligation. 
Oral combined contraceptive usage was very low at 3.8% (130/3408). A relatively large 
number of women were smokers 19.4% (769/3958). Just less than 60% of the women 
were HIV positive, and 77.1% (1768/2294) were on HAART with an overwhelming 
majority still on first-line treatment 89.1% (1505/1689).  A majority had a CD4 count ≤ 
500 74.3% (1321/1779).  A fifth of the patients 20.3% (818/4036) had a positive history 
of tuberculosis (previous or active infection). 
Table 1: Baseline characteristics: Demographics and medical history 
Variables 
 
 
Median age (years), n=4035 and missing data= 
0.02% (1/4036) 
 37, range 18-83  
Median Parity, n=3946 and missing data= 2.2% 
(90/4036) 
2, range 0-10 
Menopausal status, n=4012 and missing data= 
0.6% (24/4036) 
%(n/n) 
Premenopausal  84.3(3384/4012) 
Post-menopausal 15.7(628/4012) 
Contraceptive use, n= 3408 %(n/n) 
None  42.1(1435/3408) 
Injection  40.1(1367/3408) 
Tubal ligation 8.8(300/3408) 
Oral combined contraceptive (OCP)  3.8(130/3408) 
Others 5.2(176/3408) 
Duration of OCP use, n= 98 and missing data= 
24.6% (32/130) 
%(n/n) 
 
≤ five years 71.4(70/98) 
> five years  28.6(28/98) 
Smoking status, n= 3958 and missing data= 1.9% 
(78/4036) 
%(n/n) 
Yes 19.4(769/3958) 
No  80.6(3189/3958) 
HIV status, N=4036 % (n/N) 
Positive  59.7(2409/4036) 
Negative  30.1(1215/4036) 
27 
Unknown 10.2(412/4036) 
Taking anti-retroviral treatment, n=2294 and 
missing data= 4.8% (115/2409) 
% (n/n) 
Yes (n=1768) 77.1(1768/2294) 
No (n= 526) 22.9(526/2294) 
Anti-retroviral treatment, n= 1689 and missing 
data= 4.5% (79/1768) 
%(n/n) 
First line 89.1(1505/1689) 
Second line 10.7(180/1689) 
Third line 0.2(4/1689) 
CD4 count, n= 1779 and missing data= 26.2% 
(630/2409) 
%(n/n) 
≤500 74.3(1321/1779) 
> 500 25.7(458/1779) 
Tuberculosis (previous or active infection), 
N=4036 
%(n/N) 
No 79.7(3218/4036) 
Yes 20.3(818/4036) 
Diabetes Mellitus, N=4036 %n(N) 
No 96.2(3384/4036) 
Yes 3.8(152/4036) 
Summary of table 2 
Between 01 January 2010 to 31 December 2015, 7601 women were referred to the Groote 
Schuur Hospital colposcopy clinic. Referral cytology was ≥HSIL in 53.1% (4036/7601) 
women. We excluded 0.2% (13/7601) women without any entries in the database. 
Table 2: Indications for referrals to colposcopy clinic 2010-2015 
Referral cytology n (%) 
≥HSIL Pap smears 4036(53.1) 
Non- HSIL Pap smears, vulval HSIL, genital warts and others 3552(46.7) 
Missing data 13 (0.2) 
N (%) 7601 (100) 
Summary of table 3 
Colposcopic findings were not documented in 13.8% (555/4036) women. Colposcopic 
assessment data were available for 85.1% (3434/4036) women, and colposcopy was not 
indicated in 1.0% (40/4036) women because they had macroscopic cancer. Half of the 
women who had colposcopy 50.3% (1728/3434) had an excisional procedure (LLETZ or 
cone biopsy) performed at the same sitting. In a third 33.0% (1132/3434) of the women, 
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a punch biopsy was performed for histological confirmation of the diagnosis before 
definitive treatment. 
Table 3: Management on the referral visit 
Colposcopy examination performed, n= 3481, missing 
data= 13.8% (555/4036)  
%(n/N) 
Yes 85.1(3434/4036) 
No (macroscopic cancer) 1.0(40/4036) 
No   0.2(7/4036) 
Management after colposcopy, N=3434 %(n/N) 
Excisional procedure (LLETZ or cone biopsy) on the same day 50.3(1728/3434) 
Punch biopsy  33.0(1132/3434) 
*Other  16.7(574/3434) 
*premarin, antibiotics, repeat Pap smear 
 
Summary of table 4 
A quarter 27.7% (41/148) of the women with normal colposcopic findings had CIN2+ on 
histology. A third 33.3% (30/90) of the women with atrophic changes at colposcopy had 
CIN 2+ on histology. More than a third 38.1% (222/583) with minor colposcopic changes 
had CIN 2+ on histology. In the women with inadequate colposcopy, 41.5% (17/41) had 
CIN 2+ on histology. More than half 58.3% (14/24) of the women with inflammatory 
changes had CIN 2+ on histology. Colposcopic major changes were confirmed 
histologically in 76.5% (1528/1997) women. Suspicion of microinvasion at colposcopy 
was confirmed in 7.1% (6/84) of the women. More than half 51.2% (43/84) of those with 
colposcopic findings suggestive of microinvasion had CIN 2+ on histology. 
 
Table 4: Colposcopic and afinal diagnosis of the referral visit 
 aFinal diagnosis 
 
Colposcopic diagnosis 
%(n/N) 
Histology (cervical 
biopsy, LLETZ or cone 
biopsy) 
%(n/n) 
Cytology 
%(n/n) 
*Normal, n =148 and 
missing results= 31.8% 
(69/217) 
 
 
Normal  
 
4.7(7/148) Normal  23.6(35/148) 
CIN 1  
 
13.5(20/148) ASCU-
S/LSIL 
10.8 (16/148) 
CIN 2+  
 
27.7(41/148) ASC-H/HSIL 18.9(28/148) 
*Minor changes, n= 583 
and missing results= 
12.6% (84/667) 
Normal  
 
5.3(31/583) Normal  6.3(37/583) 
CIN 1 
 
42.0(245/583) ASC-
US/LSIL 
4.3(25/583) 
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CIN 2+ 
 
38.1(222/583) ASC-H/HSIL 3.6(21/583) 
*Major changes, n=1997 
and missing results= 
8.0% (173/2170) 
Normal  
 
2.9 (57/1997) Normal 4.1(82/1997) 
CIN 1 15.1(301/1997) ASC- 1.0(19/1997) 
  US/LSIL  
 CIN 2+ 
 
76.5(1528/1997) ASC-H/HSIL 0.3(5/1997) 
*Suspicion of 
microinvasion, n= 84 
and missing results= 
14.3 % (14/98) 
Normal  
 
2.4(2/84) Normal 1.2(1/84) 
CIN 1 
 
6.0(5/84) ASC-
US/LSIL 
3.6(3/84) 
CIN 2/3 
 
bMI 
51.2(43/84) 
 
7.1(6/84) 
ASC-H/HSIL 26.2(22/84) 
Inflammation, n=24 
and missing results= 
25% (8/32) 
Normal 8.3(2/24) Normal 12.5(3/24) 
CIN 1 8.3(2/24) ASC-
US/LSIL 
4.2(1/24) 
CIN 2+ 58.3(14/24) 
 
ASC-H/HSIL 8.3(2/24) 
Atrophy, n= 90 and 
missing results= 29.7% 
(38/128) 
Normal 5.6(5/90) Normal 26.6(24/90) 
CIN 1 12.2(11/90) ASC-
US/LSIL 
6.7(6/90) 
 CIN 2+ 33.3(30/90) ASC-H/HSIL 15.6(14/90) 
*Inadequate, n=41 and 
missing data= 24.1% 
(13/54) 
Normal 14.6(6/41) Normal 17.1(7/41) 
CIN 1 9.8(4/41) ASC-
US/LSIL 
7.3(3/41) 
 CIN 2+ 41.5(17/41) ASC-H/HSIL 7.3(3/41) 
Other, n=62 and 
missing data=8.8% 
(6/61) 
Normal 6.5(4/62) Normal 21.0(13/62) 
CIN 1 29.0(18/62) ASC-
US/LSIL 
4.8(3/62) 
CIN 2+ 
 
35.5(22/62) ASC-H/HSIL 3.3(2/62) 
*Colposcopic diagnosis 
missing, n= 536 and 
missing results= 3.4% 
(19/555) 
Normal 
 
3.2(17/536) Normal 21.5(115/536) 
CIN 1 
 
10.8(58/536) ASC-
US/LSIL 
3.9(21/536) 
CIN 2+ 
 
59.0(316/536) ASC-H/HSIL 1.3(7/536) 
Colposcopy not done, 
n=7  
Normal 28.5(2/7) Normal 0(0) 
CIN 1 28.5(2/7) ASC- 
US/LSIL 
0(0) 
CIN 2+ 
 
42.9(3/7) ASC-H/HSIL 0(0) 
Macroscopic cancer, 
n=40 
    
N= 4036   
 
 
aFinal diagnosis- histology or repeat cytology depending on colposcopic findings at referral 
bMI- microinvasion 
  
30 
 
*Non specified histology excluded from the table from each category; normal colposcopy 0.7% (1/148), 
minor changes 0.3% (2/583), major changes 0.3% (5/1997), suspicion of microinvasion 2.4% (2/84), 
inadequate 2.4% (1/41) & colposcopic diagnosis missing 0.4% (2/536). 
 
Summary of table 4a  
The Pap smear correctly identified 74.1% (2282/3081) women with CIN 2+ on histology.  
Over a fifth 21.6% (666/3081) had CIN 1, and very few 4.3% (133/3081) had normal 
histology. 
 
Table 4a: Concordance between cytology and histology in detecting CIN2+ 
 Histological diagnosis 
Cytology CIN 2+ 
%(n/n) 
CIN 1 
%(n/n) 
Normal 
%(n/n) 
≥HSIL (histology results 
available) 
n= 3081 
 
 
74.1% 
(2282/3081) 
 
21.6(666/3081) 
 
4.3% (133/3081) 
Excluded 955 women from analysis; missing results n= 424, histological diagnosis not specified n= 13, 
cytology repeated n= 518 
 
Summary of table 4b 
Colposcopy sensitivity = 83.7% (95% CI 82.0%-85.4%), specificity= 47.0% (95% CI 
43.2%-50.8%), positive predictive value (PPV) = 81.2 % (95% CI 80.1%-82.3%), negative 
predictive value (NPV) = 51.3% (95% CI 48.0%-54.5%) and diagnostic accuracy= 73.9% 
(95% CI 72.1%- 75.6%). It is important to note that women with two LSIL Pap smears who 
also had colposcopic examination were not included in this calculation since only women 
with HSIL Pap smears were analysed. 
Table 4b: *Specificity, sensitivity, PPV, NPV and diagnostic accuracy of 
colposcopy in detecting CIN2+ 
 Histological diagnosis 
 
 ≥CIN 2+ 
n 
Other (LSIL, atrophy, 
inflamed or normal) 
n 
Colposcopic 
diagnosis 
≥ major changes 
(HSIL) 
n=1942 
 
1577 
 
 
365 
 
Other (LSIL, 
atrophy, inflamed or 
normal) 
 
n=630 
 
307 
 
 
323 
*Excluded 1464 women from analysis; inadequate colposcopy n= 41, other colposcopic diagnosis n= 62, no 
colposcopic diagnosis n= 536, colposcopy not done n= 7, macroscopic cancer n= 40, no histological diagnosis n=424, 
cytology repeated n= 344 and other histological diagnosis= 10 
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Summary of table 5 
The Pap smear correctly identified 81.5% (1311/1609) women with CIN 2+ on histology.  
Over a tenth 13.2% (212/1609) had CIN 1, and very few 5.3% (86/109) had normal 
histology. 
Table 5: Concordance between cytology and histology in detecting CIN2+ in 
women who had an immediate LLETZ or cone biopsy 
Histological diagnosis 
Cytology 
CIN2 + 
%n(n/n) 
CIN 1 
%(n/n) 
Normal 
%(n/n) 
≥HSIL 
n=1609 81.5(1311/1609) 13.2(212/1609) 5.3(86/1609) 
Excluded 114 patients from the analysis; missing histological results n = 111 and histological diagnosis not specified 
n = 3 
Summary of table 5a and 5b 
Colposcopic major changes were confirmed histologically in 81.7 % (1198/1467) of the 
women after immediate treatment with LLETZ. The majority 80 % (8/10) of the women 
who had a diagnostic cone biopsy after a normal colposcopic examination had CIN2+ on 
histology. Of those with minor changes, more than two thirds 68.9% (31/45) had CIN 2+ 
on diagnostic cone biopsy. Microinvasion was confirmed after a diagnostic cone biopsy in 
12.2% (6/49) of the women who had a suspicion of microinvasion at colposcopy. The 
majority of the women who had a suspicion of microinvasion on colposcopy, 79.6% 
(39/49) had CIN 2/3. Almost three quarters 71.4% (5/7) of the women with atrophic 
changes at colposcopy had CIN 2+ on diagnostic cone biopsy. In women with inadequate 
colposcopy, 58.8 % (10/17) had CIN 2+ on diagnostic cone biopsy. In women who 
underwent ‘look and LLETZ’, there was overtreatment in 18.2% (193/1467). 
Table 5a: *Concordance between colposcopy and histology in detecting 
CIN2+ in women who had immediate treatment with LLETZ 
Histological diagnosis 
Colposcopic diagnosis 
≥CIN2+ 
%(n/N) 
CIN 1 
% (n/N) 
Normal 
%(n/N) 
≥Major changes, n= 
1467 and missing 
results= 6.3% 
(98/1565) 
81.7(1198/1467) 13.2 (193/1467) 5.0 (74/1467) 
Overtreatment 18.2% (267/1467) 
*Women with other histology excluded from analysis; n=2
  
32 
 
 
Table 5b: *Concordance between colposcopy and histology in 
detecting CIN2+ in women who had a diagnostic cone biopsy 
 Histological diagnosis 
 
Colposcopic diagnosis 
≥CIN2+ 
% (n/N) 
CIN 1 
% (n/N) 
Normal  
%(n/N) 
Normal N= 10 and missing 
results= 16.7% (2/12) 
 
80 (8/10) 10 (1/10) 10 (1/10) 
Minor changes N= 45 and 
missing results=6.3% 
(3/48) 
 
68.9 (31/45) 22.2(10/45) 8.9 (4/45) 
Atrophy N= 7 and missing 
results=12.5% (1/8) 
 
71.4 (5/7) 14.3 (1/7) 14.3 (1/7) 
Suspicion of microinvasion 
N= 49 and missing 
results=3.9% (2/51) 
 
91.8 (45/49) 8.2 (4/49) 0 (0) 
Inadequate N= 17 and 
missing results=19.8 (4/21) 
58.8(10/17) 5.9 (1/17) 29.4 (5/17) 
*Excluded 130 women from the analysis; other colposcopic diagnosis n= 7, no colposcopic diagnosis n= 
10, other histology n=2, missing histological diagnosis n=111 
 
Summary of table 6 
The overall complication rate was 7.2% (117/1628). The risk of infection 3.8% (54/1628) 
was similar to that of bleeding 3.3% (62/1628). 
Table 6: *Excisional procedure (LLETZ or cone biopsy) complications 
Excisional procedure (LLETZ or cone biopsy) 
complication, n= 1628 and missing results= 3.8% 
(64/1692) 
%(n/n) 
Yes  
No  
 
7.2(117/1628)  
92.8(1511/1628) 
 
Complications n=117 
 
%(n/n) 
Bleeding, n=62 
Infection, n=54 
Other, n=1 
 
 53.0(62/117)  
46.2(54/117) 
0.9(1/117) 
 
 
* In women who had multiple excisional procedures, only complications of the last procedure were recorded    
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Summary of table 7 
Persistent disease was observed in 17.0% (206/1213) women, and 61.2% (742/1213) 
women were considered cured. 
Table 7: Post-treatment results (using colposcopy and or cytology and or 
histology results) 
Result %(n/N) 
Persistent disease 17(206/1213) 
Cured 61.2(742/1213) 
ASC-US/ LSIL 21.5(261/1213) 
Other histology 0.3(4/1213) 
Total 1213 
Excluded 426 women; 383 with no results, 14 with inadequate histology, and 29 who had a diagnostic cone biopsy 
and needed further treatment 
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Summary of figure 1 
At 24 months 5.9% (12/204) women still had persistent disease. Cancer was a rare 
outcome; it occurred in 0.5% (1/202) of women in this group. The default rate at 24 
months was very high at 73.0% (149/204). 
Figure 1: Long-term outcomes of women who had persistent disease after 
initial treatment (using colposcopy and or cytology and or histology results) 
 
*Excluded from analysis women with inadequate or other histology; n= 4 at 10months, n= 3 at 16 months, n= 1 at 
18 months and n= 2 at 24 months  
*Women with persistent disease had repeat excisions if their histology confirmed HSIL 
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Summary of figure 2 
Recurrence was very low, and it peaked at ten months at 1.5% (11/740), and by 24 months 
the cumulative recurrence rate was 4.6% (34/742). Default rate at 24 months was very 
high at 88.9% (660/742). No women developed cancer in this group.  
Figure 2: Long-term outcome of women who were considered cured after 
initial treatment (using colposcopy and or cytology and or histology results) 
*Excluded from analysis women with inadequate or other histology; n= 2 at 10months, n= 2 at 16 months, n= 1 at
18 months, n= 1 at 30 and 36 months
Summary of outcomes in the two groups 
The overall risk of developing cancer in the two groups was 0.5% after 60 months of follow 
up. The mean default rate at 24 months was very high at 81%. 
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Summary of table 8 
In the univariate analysis, parity >=4 was associated with a higher risk of disease 
recurrence (p=0.0004). In the multivariate analysis, taking HAART was associated with 
a reduced risk of disease recurrence and being menopausal was associated with an 
increased risk of disease recurrence. 
 
Table 8: Univariate & multivariate analysis of disease recurrence in women 
considered cured after the initial treatment.   
Variable Univariate  Multivariate 
Variable HR 95% CI P-
value 
HR 95% CI P-
value 
Age             
30-65 2.83 0.379-21.15 0.311 - - - 
>65 2.081 0.0-inf 0.997 - - - 
        
   
Parity       
   
>=4 4.912 2.033-11.860 0.0004* - - - 
              
Postmenopausal             
Yes 1.748 0.578-5.282 0.323 13.03 1.190-142.4 0.0353
* 
              
HIV Status             
Positive 1.288 0.492-3.372 0.606 - - - 
              
CD4             
>500 0.864 0.168-4.455 0.861 0.694 0.117-4.12 0.688 
              
HAART             
Yes 0.283 0.076-1.054 0.06 0.109 0.015-0.768 0.0261* 
              
Smoking             
Yes 0.839 0.305-2.306 0.733 - - - 
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Summary of table 9 
In the univariate analysis, age > 65 years was associated with delayed clearance of 
disease after retreatment for persistent disease (p= 0.00036) 
 
Table 9: Univariate & multivariate analysis for disease clearance after 
retreatment in women who had persistent disease after the initial treatment 
Variable Univariate  Multivariate  
HR 95% CI P-value HR 95% CI P-
value 
Age 
      
30-65 0.923 0.463-1.842 0.820 - - - 
>65 62.968 6.477-612.120 0.00036* - - -        
Parity 
      
>=4 1.125 0.600-2.108 0.714 1.980 0.476-
8.287 
0.346 
       
Postmenopausal   
     
Yes 0.975 0.594-1.601 0.920 1.120 0.421-
2.992 
0.818 
       
HIV status 
      
Positive 0.777 0.519-1.162 0.218 - - -        
CD4 
      
>500 1.061 0.550-2.048 0.860 0.90
5 
0.440-
1.861 
0.785 
       
HAART 
      
Yes 1.018 0.559-1.854 0.953 0.921 0.442-1.916 0.825        
Smoking 
      
Yes 0.866 0.514-1.459 0.589 0.364 0.111-1.192 0.0951        
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CHAPTER 4: DISCUSSION 
 
4.1 Colposcopic clinic workload 
 
GSH colposcopy clinic is run by four gynaecology oncology subspecialists; three 
experienced colposcopists who are general practitioners and two gynaecology oncology 
subspecialist trainees. To remain proficient in colposcopy, some colposcopy quality 
control programmes recommend that a colposcopist must see more than 50 new referrals 
in a year (38). In the study period, 7601 women were seen in the GSH colposcopy clinic 
(1520 women/ year), and 4036 of those women had been referred for an HSIL Pap smear. 
Of the 4036 women with HSIL, 3434 women had documentation that they underwent a 
colposcopic examination. Therefore, each colposcopist attended to about 170 new 
referrals yearly (1520 women/year/ 9 colposcopists) during the study period. Since 3434 
women were documented to have undergone colposcopic assessment, each colposcopist 
perfomed about 76 colposcopies/ year on women who had been referred for an HSIL Pap 
smear. This workload meets the recommendation of most colposcopy quality control 
programmes.  
 
4.2. Sociodemographic and clinical characteristics 
Cervical cancer screening in South Africa is still opportunistic. However, the South 
African cervical cancer screening policy recommends that from the age of thirty years, 
asymptomatic women should have three ten-yearly Pap smears free of charge (9). The 
median age of women referred with an HSIL Pap smear in this study was 37 years, range 
(18-83 years). In a group of unscreened South African women, the mean age of diagnosis 
of HSIL was 37.7 years, and this was higher in comparison to Europe or Northern USA 
(77). The mean age of diagnosis was lower in Europe or Northern USA because cervical 
cancer screening starts at the age of 25 years in most European countries and 21 years in 
Northern America. Earlier age of screening then translates to younger age at diagnosis. 
The median age in our study was similar to others done in resource-constrained 
environments. In a study conducted in Turkey, a middle-income country like SA, which 
looked at the age trends in HSIL and cancerous lesions of the uterine cervix, the peak-age 
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incidence of HSIL was in the 30–39 years age group (78). In the same study, the mean 
age at diagnosis of HSIL was the same as in this study, 37.7 years.  
The median parity in the study was two, range (0-10). Between 2007 and 2017, fertility 
has declined from an average of 2,7 to 2,4 children in South Africa (79). The median parity 
in this study is therefore consistent with the South African census data. There is some 
published literature showing an association between parity of four or more with a high 
incidence of low and high grade squamous intraepithelial lesions (78).  
Injectable progestogen contraceptives were the commonest form of contraception used 
by more than a third 40.1% (1367/3408) of women in this study. There is conflicting data 
on whether the use of injectable progestogen contraceptives especially 
medroxyprogesterone acetate increases the risk of HIV acquisition (80-82). Despite this, 
injectable progestogen contraceptives have remained the contraceptive of choice among 
South African women. Injectable progestogen contraceptives were used by 24% and 26% 
of married and unmarried sexually active women respectively (83). On the other hand, 
45.4% and 35.8% of married and unmarried sexually active women respectively were not 
using any form of contraception (83). Similarly, in this study, 42.1% (1435/3408) of 
eligible women were not on contraception. The reason why such a high number of women 
in the reproductive age group were not using any form of modern contraception needs to 
be explored further. There might be an opportunity to link cervical cancer screening and 
family planning services to reduce the unmet need of contraception in South Africa which 
stands at 14.7% in married women and 24% in sexually active single women (83).  
Smoking and HIV infection are known risk factors for developing cervical HSIL and 
invasive cancer. In this study, a relatively large number of women were smokers 19.4% 
(769/3958). The prevalence of smoking in black South African women is very low at 3% 
compared to 38% and 15% in mixed-race and white women respectively (83). Smoking is 
more prevalent in urban women compared to those living in rural areas (83). Western 
Cape Province has the highest prevalence (25%) of smoking women in the whole of South 
Africa (83). All these factors contribute to the relatively high prevalence of smoking 
among women attending the GSH colposcopy clinic during the study period. 
Unfortunately, in the GSH colposcopy database, the race of the women was not captured 
so it was not possible to show the distribution of smoking according to race.  
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Almost 60% of the women in this study were HIV positive, and an overwhelming majority 
were on first-line highly active antiretroviral treatment 89.1% (1505/1689). The 
prevalence of HIV in this study was much higher than the prevalence of 12.6% in the total 
South African population and 22% in women of reproductive age group (79). Cervical 
cancer screening has been incorporated as the standard of care in most HIV treatment 
programmes. Cervical cancer screening in HIV programmes leads to selection bias since 
more HIV-infected women are screened and referred for colposcopy compared to HIV 
uninfected women who may not be accessing health services. Most patients had a CD4+ 
count less than 500 cells/ mm 3. HIV viral load data was not performed or entered into 
the GSH colposcopy database during the study period. In some colposcopy clinics in high-
income countries, HIV-infected women are virtually unseen (84). A study in women 
attending colposcopy services at Chris Hani Baragwanath Hospital in the Gauteng 
Province of South Africa had similarly high rates of HIV infection (85). The high burden 
of HIV infection in women attending the colposcopy clinic during the study period was 
also highlighted by the high rates of tuberculosis (previous and active infection), an 
opportunistic infection which affected 20% of these women. 
 
4.3. Colposcopic assessment 
The colposcopic examination is an integral part of any successful cervical cancer 
screening programme. An HSIL Pap smear is an indication for referral for colposcopic 
assessment. Colposcopic examination allows magnification and visualisation of the cervix 
for diagnostic biopsies or treatment to be done under direct vision. An overwhelming 
majority of women in this study had a colposcopic assessment, 85.1% (3434/4036). Of 
concern is that 1.0% (40/4036) of women did not need colposcopic assessment because 
they already had macroscopic cancer on pelvic examination. These women were not 
candidates for colposcopy clinic referral but should have been referred straight away to 
gynaecological oncology hospital services for assessment and treatment. Much time was 
wasted while they waited for their colposcopy appointment. Inappropriate referrals for 
women with macroscopic cancer highlights the fact that healthcare workers involved in 
cervical cancer screening programmes need adequate training in recognising 
macroscopic cervical cancer to avoid delays in women accessing appropriate cancer care. 
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4.4. The colposcopic assessment followed by immediate treatment (see and 
treat) 
In low-resource settings, loss to follow-up in cervical cancer screening studies is 
unacceptably high (86-88). As one of the auditable standards, The National Health 
Service Cervical Screening Programme in the UK recommends that loss to follow-up 
should not exceed 15% (38).  
In low-resource settings, one way to mitigate the high loss to follow-up is by treating 
women with concordant high-grade cytology and colposcopic finding at the same sitting 
without histological confirmation of HSIL (‘see and treat’). Cervical cancer screening 
programmes initially involve three visits to a healthcare facility (first a screening visit, a 
second visit for triaging with colposcopy and taking directed biopsies and the third visit 
for treatment of biopsy-proven HSIL). In “see and treat’ programmes, there are only two 
visits involved, and treatment is done on the second visit in those who are screen-positive 
after a colposcopic assessment without any prior histological confirmation of HSIL by a 
punch biopsy. This approach is different from “screen and treat’ which entails only one 
visit for screening and treatment of all those who are screen positive on the same day. In 
‘screen and treat’ the likelihood of overtreatment is high. ‘See and treat’ has been shown 
to be effective, acceptable and leads to a reduction in loss to follow-up by reducing the 
number of visits to a health-care facility (89-94). At GSH colposcopy clinic, women with 
discordant results, that is high-grade cytology, but normal and minor changes at 
colposcopy can have a diagnostic cone biopsy which turns out to be therapeutic in most 
of the cases as well when the lesion is fully excised with clear margins. In the study period, 
more than half of the women 50.3% (1728/3434) had either ‘see and treat’ or had a 
diagnostic cone biopsy performed on the referral visit. A third of the women had routine 
care that is having colposcopically directed punch biopsies before definitive treatment.  
4.5. Concordance between cytology and histology in detecting CIN2+ 
One of the prerequisites of a good cervical cancer screening programme is reliable 
cytopathological services. One of the many reasons why cytology-based screening has 
failed in many low- and middle-income countries is the expense and complexity involved 
in setting up reliable cytopathological services and a shortage of well-trained 
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cytotechnicians and cytopathologists. In South Africa, all the Pap smears are analysed at 
the National Health Laboratory Service (NHLS). In the Western Cape Province, Pap 
smears are only analysed at the two tertiary hospitals, Groote Schuur and Tygerberg. 
Almost all the patients seen at GSH colposcopy clinic during the study period had their 
Pap smears processed at GSH NHLS. At the GSH NHLS, they have 11 cytotechnicians, 
and they have robust internal quality control procedures which include histology and 
cytology correlation every three to four months. The lab has external accreditation with 
the Royal College of Pathologists of Australia Quality Assessment Programs (RCPAQAP). 
At GSH NHLS they process about 60 000 Pap smears yearly. One of the key performance 
indicators of the cervical cancer screening programme in the UK is that cytology 
laboratories must screen more than 35 000 Pap smears annually to maintain proficiency 
(95). One way of assessing the quality of the cytopathological services in cervical cancer 
screening is by looking at the concordance between HSIL Pap smears and histology which 
is the gold standard in the diagnosis of CIN2+. In this study, the concordance between 
cytology and histology was high.  Three-quarters 74.1% (2282/3081) of women with HSIL 
Pap smears had CIN 2+ confirmed on histology. One South African study found a similar 
concordance of 71.8% between cytology and histology (85). In a study done in Brazil, a 
middle-income country like SA, the concordance between HSIL cytology and histology 
was 76% which was also similar to ours (96). In this study, the rate of discordance between 
cytology and pathology was 25.9% which is in keeping with other studies that have found 
rates of discordance between 11-28% (97-99). In a study that was done in British 
Columbia, a high-income setting, the overall correlation between cytology and biopsy was 
79.4% (100). 
 
4.6. Sensitivity, specificity, PPV, NPV and diagnostic accuracy of colposcopy 
in detecting CIN2+ 
In this study, the sensitivity and specificity of colposcopy in detecting CIN2+ was 83.7% 
(96% CI 82.0%-85.4%) and 47.0% (95% CI 43.2%-50.8%) respectively. In a meta-analysis 
of nine studies, for the threshold of normal cervix and LSIL compared with HSIL and 
cancer, the weighted average sensitivity and specificity was 85% and 69% respectively 
(101). In a study done in British Columbia, colposcopy had a sensitivity and specificity of 
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90.3% and 57.3% respectively (100). In another study, the sensitivity and specificity of 
colposcopy in detecting any lesion was 89% and 52% respectively (102). In the same 
study, the sensitivity for CIN 2/3 was 56%(102).  The PPV and NPV of colposcopy in 
detecting CIN2+ in this study was 81.2% (95% CI 80.1%-82.3%) and 51.3% (95% CI 
48.0%-54.5%) respectively. One study found colposcopy to have a PPV and NPV of 72.3% 
and 47.7% respectively (103). Another study showed a PPV of 75.5% which is similar to 
this study (104).  
More than half of the women in this study period had LLETZ or diagnostic conisation 
performed at the same sitting. This practice was implemented to minimise the impact of 
very high rates of loss to follow-up experienced in cervical cancer screening programmes 
in low-income countries (86-88). However excisional procedures are not without risk. 
Besides the relatively more common risks of haemorrhage and infection, there is 
published literature on the association of cervical excisional procedures and pregnancy-
associated adverse events (105). Since these women are treated on the same day without 
histological confirmation of HSIL, it is imperative that their outcomes are regularly 
audited to avoid over-treatment of women without the disease. In women who had 
treatment on the same day, the concordance between cytology and histology was high at 
81.5%. The concordance between colposcopy and histology in detecting CIN 2+ was 81.7% 
(1198/1467). The NHSCSP recommends that the diagnostic concordance between 
colposcopy and histology in detecting CIN2+ to be at least 90% in women who undergo 
‘see and treat’ (38). In this study, the rate of overtreatment was 18.2% which is in keeping 
with other studies where it ranged from 4-18% (91, 93, 94, 106-109). With very high rates 
of default to follow-up particularly over time, the option of ‘see and treat’ is justifiable in 
the GSH colposcopy unit. 
4.7. Detection of CIN2+ in women undergoing a diagnostic cone biopsy for 
the discrepancy between cytology and colposcopy 
Discrepancy between cytology and colposcopy was defined as: minor or normal 
colposcopic findings in a woman with an HSIL Pap smear. At GSH colposcopy clinic, these 
women undergo a diagnostic cone biopsy which is also therapeutic in most of the cases 
particularly if the lesion is completely excised and the margins are clear. In this study, a 
majority of these women had CIN2+ on histology. In women who had normal, atrophic, 
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inadequate or minor colposcopic findings, the rates of CIN2+ on histology were 80%, 
71.4%, 58.8% and 68.9% respectively. In a study looking at outcomes in women who had 
a diagnostic LEEP for the discrepancy between cytology and colposcopy, CIN2+ was 
confirmed in two-thirds of these patients (110). Since a majority of women with HSIL Pap 
smears harbour CIN2+ regardless of the colposcopy findings, another option is to skip 
colposcopy and treat all these women with an excisional procedure. The ASCCP guidelines 
deem an excisional procedure without colposcopy as reasonable in women with HSIL Pap 
smears when colposcopy is unavailable (39). The findings of this study justify the practice 
at GSH colposcopy clinic of offering a diagnostic cone biopsy in women with the 
discrepancy between cytology and colposcopy results.  
4.8. Complications of colposcopy 
Overall the morbidity of LLETZ and cone biopsies was low at 7.2% (117/1628). The risk of 
bleeding was 3.3%, and the risk of infection was 3.8%. Most of these complications were 
reported by the women on their subsequent post-treatment visit. Data on admissions for 
complications was not consistently captured on the database. The reported complication 
rate is combined for both LLETZ and cone biopsy. LLETZ and cone biopsy complications 
were combined because the numbers were small. The other reason for reporting them 
together is that some studies have shown that the hot loop cone biopsy and LLETZ 
complications are similar (111). One study done in a high resource setting had a similar 
risk of bleeding of 3.8% (112).  However, the complication rate in this study might have 
been underestimated because, on the database, women who had multiple procedures only 
had morbidity of the last procedure captured. Although the burden of HIV infection was 
high in the study, the complication rates were comparable to other studies. In a study 
done in China, 10% of women who had LLETZ were HIV- infected and the rate of infective 
morbidity of 4.3% was comparable to this study (113). 
4.9. Cure and treatment failure rates 
A number of factors affect the cure and treatment failure (persistent or recurrent disease) 
rates in women treated for HSIL. We defined cure as any woman who had excision of 
HSIL and on the four-month follow up visit had both normal colposcopic findings and 
Pap smear result. Persistent or residual disease was defined as any woman who had 
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excision of HSIL and on the four-month follow up visit she had either major colposcopic 
findings and or ≥ ASC-H Pap smear. Recurrence was defined as any woman who had any 
one of the following; colposcopy showing major changes and or ≥ASC-H Pap smear and 
or HSIL histology after prior documented normal colposcopy and histology results. Risk 
factors for treatment failure include; positive margins on excision specimens, high grade 
of CIN, oncogenic HPV types, HIV infection, age, smoking and sexual behaviour (114-
118). In this study, the cure rate at the four-month follow-up visit was 61.2% (742/1213). 
This is in keeping with other studies done in countries with a similar high burden of HIV 
but much lower than reported in countries with a lower burden of HIV (101, 119-121). 
However, this study probably underestimated the cure rate for various reasons. Until 
2017, GSH hospital colposcopy clinic protocol recommended following up women at four 
months post-treatment and thereafter six or 12 monthly depending on colposcopy and 
cytology findings. The National Health Service Cervical Screening Programme in the UK 
recommends that women should be followed up at six months post-treatment (38). 
Women with HSIL are immediately referred back for colposcopy. Those with normal, 
ASC-US and LSIL Pap smears have reflex testing of hrHPV as a test of cure. Those with a 
negative test are considered as cured and referred back to routine screening, and those 
who are positive are referred back for colposcopy since they have a higher risk of having 
residual disease. Therefore, it is possible that if we had followed up the treated women at 
six months, the cure rate was going to be slightly higher as more women were going to 
clear the disease. A fifth of the women still had ASC-US, and LSIL Pap smears at the four-
month follow-up visit. A high-risk HPV DNA test of cure on these patients would have 
triaged them into the cure or treatment failure categories. It is plausible that if we had 
done the high-risk HPV DNA test of cure, some women in this group would have been 
designated as cured. In this study, the risk of persistent disease post-LLETZ or cone 
biopsy at the four-month follow-up visit was high at 17.0%. In women cured at the four-
month follow-up visit, recurrence peaked at ten months at 1.5% (11/740) and by 24 
months; the cumulative recurrence rate was 4.6% (34/742).  
 Our findings were in keeping with other studies which found that post excisional 
treatment, 4% to 17% of women have CIN2+ due to either residual or recurrent disease 
(119-122). One study done in South Africa showed much higher rates of persistent disease 
especially in HIV infected women (118).  
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Women with the persistent HSIL at the four-month follow-up had more excisional 
treatment, and in those who did not default follow-up, the development of invasive 
cervical cancer was a rare outcome. Only one patient, 0.5% (1/202) developed invasive 
cancer. At 24 months 5.9% (12/204) women still had persistent disease.  
4.10. Impact of high loss to follow up rates 
The default rate in this study was very high, at 81.0% at 24 months. We do not have any 
way to predict the outcome in these women. The possible outcomes include; 
persistent/residual disease, recurrence, cure and invasive cancer. As shown in this study, 
the risk of developing cervical cancer after treatment is very low. Therefore, if all these 
women had been accounted for, there was going to be an increase in all our outcome 
measures. Therefore, there is a strong possibility that we might have underestimated the 
outcome measures. The problem of high default rate in low-income countries has been 
alluded to before.  
4.11 Univariate & multivariate analysis of disease recurrence in women 
considered cured after the initial treatment 
Parity >=4 was associated with a higher risk of disease recurrence. Another study also 
found an association between high parity and increased risk of recurrence (78). In the 
multivariate analysis, taking HAART was associated with a reduced risk of disease 
recurrence. Although menopausal status was associated with a higher risk of recurrence, 
the result needs to be interpreted with caution because the 95% CI was too wide (1.19-
142.40). This is most likely due to the very few numbers of women who had the outcome 
of interest.  
4.12 Univariate & multivariate analysis for disease clearance after retreatment 
in women who had persistent disease after the initial treatment 
In the univariate analysis, age > 65 years was associated with delayed clearance of disease 
after retreatment for persistent disease (p= 0.00036). This result also needs to be 
interpreted with caution due to the wide 95%CI of 6.477-612.120 
 
4.13. Mitigating loss to follow-up 
47 
Effective ways to reduce loss to follow up also need to be deployed. Home visits by 
community health care workers to track women attending cervical cancer screening has 
been shown to reduce default rates (123). The use of community healthcare workers is 
cost-effective as it increases the average per-woman costs by only 14-47 SA Rand (ZAR) 
(124). Educating and effective communication with women about the importance of 
adherence to follow-up will also go a long way in reducing the problem of loss to follow-
up. The other interventions that have been found to be moderately effective include 
intensive follow-up by mail and telephone to contact patients and providing economic 
vouchers to offset out-of-pocket expenses (125). 
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CHAPTER 5: CONCLUSION, RECOMMENDATIONS, 
LIMITATIONS AND SUGGESTIONS FOR FURTHER 
RESEARCH 
 
5.1. Conclusion  
GSH colposcopy clinic is a high volume centre with the requisite workload to maintain 
the proficiency of colposcopists or trainees working in the unit. LLETZ and cone biopsy 
are safe procedures. Majority of women who did not default follow up after being 
considered cured at four months did not recur. In women who are treated appropriately 
and do not default follow-up, cervical cancer is very rare. Taking HAART was associated 
with a reduced risk of disease recurrence. However, default to follow-up is very high, and 
there is a need to improve this for cervical cancer screening to have an impact on the 
incidence of cervical cancer in South Africa.  
 
5.2. Recommendations  
There is need to link cervical cancer screening and contraception services to cater for a 
large number of women who are not taking contraception who are seen at the GSH 
colposcopy clinic. Smoking cessation programmes must be introduced in the GSH 
colposcopy clinic given the relatively large number of women who were smokers. 
Healthcare workers involved in cervical cancer screening need to be taught how to 
identify macroscopic cancer to avoid doing unnecessary Pap smears in these women and 
delaying referring them for cancer treatment. Given the high default rates, there is need 
to increase the number of women who are treated at the same sitting (‘see and treat’). The 
practice of doing diagnostic cone biopsies in women with HSIL Pap smears and normal 
or minor colposcopic changes should be maintained. Funding should be sought to employ 
community healthcare workers who track women at home to reduce the high default 
rates. The follow-up visit should be maintained at six months and introducing high-risk 
HPV DNA test of cure should be considered as this will help in triaging women with a 
normal, ASC-US and LSIL Pap smear post-treatment. 
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5.3. Limitations 
Inherent limitations of retrospective studies like missing and incomplete data and high 
loss to follow-up were our biggest problems.  
5.4. Suggestions for further research 
There is need for qualitative research to explore further why a lot of women are lost to 
follow up 
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